Head to head
OmniAb vs Vertex Pharmaceuticals
Side-by-side on the measures that matter, with a plain-English read. Full detail: OABI · VRTX
OABI
OmniAb
4.56+4.83%
1-year price shape — +176% over the period
Quant Rating C · 68/100
vs
VRTX
Vertex Pharmaceuticals
505.64+0.66%
1-year price shape — +23% over the period
Quant Rating C · 67/100
1-year performance, rebased to 100
OmniAb edges it on the scoreable measures. OmniAb has the highest Quant Rating (68); OmniAb has done best over the past year (+176%).
| OABI | VRTX | |
|---|---|---|
| Snapshot | ||
| Sector | Biotechnology | Biotechnology |
| Last price | 4.56 | 505.64 |
| Change today | +4.83% | +0.66% |
| 1-year return | +176.4% | +23.2% |
| Market cap | $662.98M | $128.16B |
| 52-week range | 1.30 – 5.43 | 402.58 – 560.25 |
| Valuation | ||
| P/E (TTM) | -12.67 | 29.45 |
| P/E percentile, own 5-yr range | 27th | 74th |
| P/B | 2.55 | 6.33 |
| Dividend yield | 0.00% | 0.00% |
| Profitability & growth | ||
| EPS (TTM) | -0.57 | 15.32 |
| Net profit (TTM) | $-82.87M | $3.88B |
| Revenue (TTM) | $38.46M | $12.59B |
| Revenue growth (YoY) | +244.2% | +12.5% |
| Gross margin | 98.3% | 86.0% |
| Operating margin | -118.0% | 37.9% |
| Net margin | -115.1% | 35.0% |
| Free cash flow (TTM) | $-18.14M | $3.80B |
| Ownership & sentiment | ||
| Institutional ownership | 47.4% | 97.2% |
| Insider activity (12mo) | 37 buy / 13 sell | 25 buy / 25 sell |
| Short interest (% of float) | 4.9% | 1.9% |
| Analyst consensus | 100% buy (5) | 88% buy / 8% hold / 4% sell (24) |
| Analyst price target | $8 (+83%) | $580 (+15%) |
| StockVane view | ||
| StockVane Quant Rating | C (68) | C (67) |
| Company | ||
| Employees | 89 | 6,400 |
| Founded | 2015 | 1989 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.